Posted by Michael Wonder on 08 Aug 2022
Funding for lifesaving drug denied by B.C. health authority as couple struggles to fund their portion
7 August 2022 - Entrectinib, a targeted drug that had shown positive results in tumours that had the same gene expression, costs $10,200 a month.
Coverage for a potentially lifesaving drug has been denied to a Vancouver man with a stage four cancer, even though the drug is approved by Health Canada, and was prescribed by his oncologist.
